000136254 001__ 136254
000136254 005__ 20240731105611.0
000136254 0247_ $$2doi$$a10.3390/ijerph19116746
000136254 0248_ $$2sideral$$a129942
000136254 037__ $$aART-2022-129942
000136254 041__ $$aeng
000136254 100__ $$aGarcía-Roy, África
000136254 245__ $$aImprovement in the Management of Oral Anticoagulation in Patients with Atrial Fibrillation in Primary Health Care
000136254 260__ $$c2022
000136254 5060_ $$aAccess copy available to the general public$$fUnrestricted
000136254 5203_ $$a(1) Background: Evaluation and improvement of the management of patients with atrial fibrillation in treatment with oral anticoagulants from primary health care. (2) Methods: prospective quasi-experimental study, conducted on 385 patients assisted with Atrial Fibrillation (AF) at the Las Fuentes Norte Health Center, before and after the implementation of actions to improve oral anticoagulants management from October 2015 to July 2017. (3) Results: The ACO-ZAR I study revealed that the population with AF presents a global prevalence of 1.7%, an indication of oral anticoagulants of 92.1%, undertreatment of 24%, suboptimal control of vitamin K antagonists of 43%, use of antiaggregant as primary prevention of 13.42%, and primary health care monitoring of 34%. The implementation of activities aimed at improving the management of oral anticoagulants in the ACO-ZAR II study achieves a reduction in undertreatment up to 16%, in the use of antiaggregant up to 9%, and in suboptimal control up to 30%, as well as an increase in control from primary health care up to 69.2% and of the penetrance of direct oral anticoagulants up to 28%. (4) Conclusions: In conclusion, the application of activities aimed at optimizing the management of oral anticoagulants in health center patients allowed the improvement of risk assessment and registration, undertreatment, use of antiaggregant, suboptimal control of vitamin K antagonists, control by primary health care center, and the penetrance of direct oral anticoagulants. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
000136254 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000136254 592__ $$a0.828$$b2022
000136254 593__ $$aHealth, Toxicology and Mutagenesis$$c2022$$dQ2
000136254 593__ $$aPublic Health, Environmental and Occupational Health$$c2022$$dQ2
000136254 593__ $$aPollution$$c2022$$dQ2
000136254 594__ $$a5.4$$b2022
000136254 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000136254 700__ $$aSarsa-Gómez, Ana$$uUniversidad de Zaragoza
000136254 700__ $$0(orcid)0000-0002-6409-9041$$aMéndez-López, Fátima
000136254 700__ $$aUrdin-Muñoz, Blanca
000136254 700__ $$0(orcid)0000-0001-8756-114X$$aSánchez-Calavera, María Antonia$$uUniversidad de Zaragoza
000136254 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000136254 773__ $$g19, 11 (2022), 6746 [10 pp.]$$pInt. j. environ. res. public health$$tInternational journal of environmental research and public health$$x1661-7827
000136254 8564_ $$s633720$$uhttps://zaguan.unizar.es/record/136254/files/texto_completo.pdf$$yVersión publicada
000136254 8564_ $$s2662816$$uhttps://zaguan.unizar.es/record/136254/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000136254 909CO $$ooai:zaguan.unizar.es:136254$$particulos$$pdriver
000136254 951__ $$a2024-07-31-09:21:38
000136254 980__ $$aARTICLE